Legal status · updated

Is compounded tirzepatide still legal and available?

Quick answer

Yes, but on a much narrower basis than most sellers imply. The shortage that made broad compounding possible was declared over in December 2024, and both compounding off-ramps closed in early 2025. What is left is patient-specific compounding under section 503A, plus a separate FDA policy of not pursuing a pharmacy that fills four or fewer prescriptions of a given compounded product per month. Neither of those is “legal in all 50 states with any valid prescription”.

The Fifth Circuit decision upheld the shortage determination. Our index tracks 384 US sellers, with availability and evidence limits below.

Is it still being sold?

Our provider directory tracks 384 US sellers of compounded tirzepatide. The records include a mix of directly verified prices, seller claims and offers with incomplete terms. Confirm availability and the amount due with the provider before paying.

The market does move, though, and it moves by attrition rather than by anything the FDA announced. Since August 2026 we have removed 51 sellers from this index after checking them one at a time. Some had simply gone — a storefront serving “temporarily closed” on every route, a domain whose certificate had lapsed, a site answering HTTP 500 everywhere. Others were still trading and had left the category: RedBox Rx returns a working homepage containing the word “tirzepatide” zero times, and Hims closed its compounded program to new patients.

The price check log records why a seller was removed and when we saw the change. A past listing does not establish that a particular seller still offers compounded tirzepatide.

The two routes, and what each one requires

Compounded medication reaches a patient down one of two paths, and they are not interchangeable.

Section 503A is a state-licensed pharmacy compounding for one named patient against that patient’s own prescription. It still exists. But a 503A pharmacy may not make what the statute calls a product that is essentially a copy of a commercially available drug — the same active ingredient, a strength within roughly ten percent, given the same way — unless the prescriber determines and documents that this particular patient needs something significantly different. FDA guidance gives a documented allergy to an inactive ingredient as an example of a significant difference for an individual patient.

Section 503B is a registered outsourcing facility compounding at scale, without individual prescriptions. It may only use a bulk substance if that substance sits on FDA’s 503B bulks list, or if the drug is in shortage. Tirzepatide is neither. There is no 503B route to compounded tirzepatide today.

The four-prescription rule almost nobody mentions

Here is the part missing from most coverage of this question. FDA has said it does not currently intend to act against a 503A pharmacy for compounding what is essentially a copy — even with no documented clinical difference — so long as that pharmacy fills four or fewer prescriptions of that specific product in a calendar month.

Read that against how compounded tirzepatide is actually sold. A telehealth program shipping monthly refills to thousands of subscribers is not filling four prescriptions a month. A seller operating at that scale is therefore relying either on genuine, individually documented clinical need for every patient, or on something else. That is worth asking about before starting — and it is a question about the seller, not about the drug.

It also matters that this is enforcement discretion: a statement about what FDA intends to pursue, not a legal exception. It can be withdrawn without anything in the law changing.

Adding B12 does not make it a different drug

Some sellers describe a drug combined with vitamin B12 as a personalized formulation. FDA addressed this directly in its April 2026 update: a GLP-1 combined with B12 is still treated as essentially a copy where the active ingredient is given the same way at a strength within ten percent of the approved product, unless there is documented, patient-specific clinical justification for the addition.

The same reasoning applies to a non-standard strength chosen so that it does not match a commercial dose. What matters is whether an individual patient needed it, not whether the number on the vial is unusual. What each add-in is, and why a vial with one in it may not look like the approved product, is on B12, B6 and glycine.

What your state adds on top

State licensing and prescribing rules also apply. In 2024, Mississippi’s medical board issued a limited waiver for compounded GLP-1 and GIP medicines. It requires a specific unmet clinical need or a listed shortage, plus documentation of ingredient testing. Nevada’s pharmacy board separately issued a notice on enforcement after the shortage deadlines.

Check current rules with your state board. Our state-by-state directory reports where sellers say they ship.

What to ask a seller

  • Which route are you compounding under — 503A patient-specific, or something else?
  • What clinical reason will be documented for me specifically, and by whom?
  • Which pharmacy fills it, and is it licensed in my state?
  • What happens to my prescription if FDA changes its compounding policy?

A seller that answers these plainly is telling you something. So is one that does not.

Timeline

Every row links the document it came from, not a report about it.

  1. 15 Dec 2022Tirzepatide injection is added to FDA's drug shortage list. The shortage is what makes broad compounding possible at all. FDA drug shortage database
  2. 2 Oct 2024FDA first determines the shortage resolved and removes tirzepatide from the list. recited in FDA's declaratory order
  3. 7 Oct 2024The Outsourcing Facilities Association and a compounder sue FDA over that determination in the Northern District of Texas. docket, 4:24-cv-00953
  4. 11 Oct 2024On FDA's own motion the court sends the decision back to the agency to be reconsidered, and the October determination is withdrawn. declaratory order, note 2
  5. 19 Dec 2024FDA issues a declaratory order re-determining that the shortage is resolved, and sets the off-ramps: 60 days for 503A pharmacies, 90 days for 503B outsourcing facilities. FDA declaratory order
  6. 5 Mar 2025The court declines to pause FDA's decision while the case runs. The deadlines hold. FDA statement log
  7. 10 Mar 2025FDA confirms the 503A off-ramp for tirzepatide has closed. FDA statement log
  8. 19 Mar 2025The 503B off-ramp closes. From here an outsourcing facility has no route to bulk tirzepatide at all. FDA statement log
  9. 13 May 2025The district court rules for FDA on the merits and the case is terminated at that level. The compounders appeal to the Fifth Circuit. docket, 4:24-cv-00953
  10. 1 May 2026FDA proposes to leave semaglutide, tirzepatide and liraglutide off the 503B bulks list. The proposal does not change the list. 91 FR 23431, docket FDA-2018-N-3240
  11. 26 Jun 2026FDA extends the comment period on that proposal by thirty days. 91 FR 38719
  12. 30 Jul 2026The extended comment period closes. 91 FR 38719
  13. 27 Aug 2026The Fifth Circuit affirms the district court's judgment in favor of FDA over the tirzepatide shortage decision. Fifth Circuit, No. 25-10600
  14. 19 Oct 2026The Fifth Circuit mandate issues in the tirzepatide appeal. U.S. Government Publishing Office court record

What we could not verify

FDA’s 503B notice is a proposal. We found no final determination in the Federal Register through November 10, 2026. The timelines cover federal actions and the named litigation. State rules and individual prescriptions require separate checks.

Informational only. This is not legal advice and not medical advice, and it describes the federal position rather than any individual seller’s compliance with it — which a price index cannot determine and does not claim to.